January 30 – February 1 2018 |
Boston, MA
The 2018 DNA Damage Response Therapeutics Summit was the first industry-dedicated meeting focused on identifying the next generation of DNA damage response therapeutics, achieving efficacy across a range of contexts, optimizing synthetic lethal screening techniques and exploiting key targets of mechanisms of resistance.
Across 3 content-packed days, the field’s thought leaders from AstraZeneca, Tesaro, Artios, Metabomed, Sierra Oncology and many more shared their insights and lessons learned, collectively enabling the community to:
- Therapeutically Exploit Synthetic Lethal Interactions for Targeted Cancer Therapy
- Optimize the Discovery, Clinical Development & Commercialization of Novel Cancer Therapies Based on the Genetic Concept of Synthetic Lethality
- Leverage Advances in DNA Sequencing and CRISPR-Based Target Discovery to Generate Breakthrough Medicines
Testimonials from our Past Events in the Cell and Viral Immunotherapy Space:
“Overall an excellent program with topical presentations and great opportunities to network with leaders in the field. The fact that it was a very focused meeting with high level people made such interactions possible and made it hugely valuable.”
Virttu Biologics
This Summit is for:
|
 |
Media Partner
Sponsors
